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Abstract 24 
Monosodium glutamate (MSG) is a suspected obesogen with epidemiological evidence 25 
positively correlating consumption to increased body mass index and higher prevalence of 26 
metabolic syndrome.  27 
ELISA and high content analysis (HCA) were employed to examine the disruptive effects of 28 
MSG on the secretion of enteroendocrine hormone glucagon-like peptide-1 (GLP-1) and 29 
GLP-1 receptor (GLP-1R), respectively. Following 3 h MSG exposure of the enteroendocrine 30 
pGIP/neo: STC-1 cell line model (500 μg/ml) significantly increased GLP-1 secretion (1.8 31 
fold; P<0.001), however, 72 h exposure (500 μg/ml) caused a 1.8 fold decline (P<0.05). 32 
Also,3 h MSG exposure (0.5-500 μg/ml) did not induce any cytotoxicity (including multiple 33 
pre-lethal markers) but 72 h exposure at 250-500 μg/ml, decreased cell number (11.8-26.7%; 34 
P<0.05), increased nuclear area (23.9-29.8%; P<0.001) and decreased mitochondrial 35 
membrane potential (13-21.6%; P<0.05). At 500 μg/ml, MSG increased mitochondrial mass 36 
by 16.3% (P<0.01). MSG did not agonise or antagonise internalization of the GLP-1R 37 
expressed recombinantly in U2OS cells, following GLP-1 stimulation. In conclusion, 72 h 38 
exposure of an enteroendocrine cell line at dietary levels of MSG, results in pre-lethal 39 
cytotoxicity and decline in GLP-1 secretion. These adverse events may play a role in the 40 
pathogenesis of obesity as outlined in the obesogen hypothesis by impairing GLP-1 secretion, 41 
related satiety responses and glucose-stimulated insulin release.  42 
Key terms: Monosodium glutamate, in vitro bioassays, high content analysis, GLP-1, 43 
diabetes; obesity 44 
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1. Introduction 51 
The incidence of obesity and metabolic diseases such as diabetes has risen dramatically over 52 
the past two decades. The United Kingdom (UK) is officially the most obese country in 53 
Europe with 1 in 5 adults overweight and 1 in 15 adults obese. It is predicted that the number 54 
of obese individuals will soar by a staggering 73% to 26 million people in the UK over the 55 
next twenty years. This is expected to fuel increases in cases of diabetes which in 2010 were 56 
estimated at 285 million worldwide with a predicted increase by 54% in 2030 due to 57 
population growth, ageing of populations and urbanization with associated lifestyle change 58 
(Shaw et al., 2010). Increased caloric intake and decreased physical activity are undoubtedly 59 
the major drivers of these increases but other factors have been highlighted (COT, 2013). 60 
Several lines of evidence, including several human epidemiological studies, suggest that 61 
certain chemicals in the diet or environment (referred to as ‘obesogens’) play a role in 62 
promoting obesity  (Sharpe and Drake, 2013).  63 
Monosodium glutamate (MSG) is a flavour enhancer used in many household prepared and 64 
processed foods worldwide which has recently been highlighted as a suspected dietary 65 
obesogen (Holtcamp, 2012). It is also believed that the effects of MSG are compounded 66 
further by its widespread availability in manufactured foods and the high frequency with 67 
which some individuals consume it (Mercola, 2009). A study investigating the effect of a 68 
lipid-containing meal with added MSG (2000 mg/meal) on glucose homeostasis, incretin 69 
secretion and gastric emptying in humans demonstrated GLP-1 plasma levels were 70 
significantly increased (Hosaka et al., 2012).. This demonstrates that exposure to MSG can 71 
have effects on the regulation of gut hormone secretion and consequently, glucose and weight 72 
homeostasis  and highlights its potential to act as an endocrine disruptor. 73 
The reported daily MSG intake of individuals varies greatly across the population. The 74 
reported UK average intake in 1991 was 580 mg/day for the general population but 4.68 75 
g/day for excessive consumers. In 2000, the average intake ranged from 300-1000 mg/day in 76 
industrialised countries (Husarova and Ostatnikova, 2013).  However, more recent studies 77 
state that the average intake of MSG is around 0.4 g/day in Europe and has been steadily 78 
increasing (Collision et al., 2009, He et al., 2011, Nakanishi et al., 2008). It is also important 79 
to consider Asian countries, where MSG consumption is much higher than other parts of the 80 
world. A study conducted in China found that the mean intake of MSG for the entire 81 
population was 3.1 g/ day (Shi et al., 2014). Current legislation does not impose any limit on 82 
the amount of MSG that restaurants or the food industry can add to their products. 83 
Furthermore, food processors and manufacturers are not obligated to list the amount of MSG 84 
on their packaging. This anomaly makes it difficult to accurately monitor levels of MSG 85 
consumption and underestimations most likely occur. 86 
A number of studies have investigated potential links between MSG, obesity and other 87 
metabolic disorders such as diabetes. In a longitudinal study, He et al. (2011) examined the 88 
association between MSG consumption and the incidence of overweight adults, reporting that 89 
a cumulative mean (± standard deviation) MSG intake of 2200 ± 1600 mg/day is associated 90 
with an increase in body mass index (BMI) after adjustment for potential confounders. The 91 
extent of weight gain in MSG users compared with non-users was modest. However, there is 92 
still major public health interest in knowing whether weight gain is modulated by MSG 93 
intake. Further studies are necessary to investigate potential mechanisms where MSG could 94 
enhance the risk of obesity/diabetes (He et. al., 2011). A study conducted in Thailand 95 
reported a significantly higher prevalence of metabolic syndrome in the tertile with the 96 
highest MSG intake. Furthermore, for every 1000 mg more MSG intake per day, the risk of 97 
having metabolic syndrome or being overweight increased, regardless of the individual’s total 98 
energy intake or physical activity level (Insawang et al. 2012).  99 
Epidemiological studies and animal studies demonstrate an association between MSG 100 
consumption/MSG-injected models and weight gain (Clough et al., 1986; He et al., 2008; 101 
Hirata et al., 1997; Insawang et al., 2012; Iwase et al., 1998; Olney, 1969; Svidnicki et al., 102 
2013). Miskowiak et al. (1993) found that rats administered with MSG displayed abnormal 103 
growth, obesity and reduced mass of the pituitary glands and testes, and also lower 104 
testosterone levels.  105 
Most known or suspected obesogens are endocrine disruptors (EDs). Many are widespread 106 
with exposure suspected or confirmed as quite common (Holtcamp, 2012). Metabolic 107 
disorders may be influenced by endocrine disrupting interactions between consumed MSG 108 
and the hormones involved in controlling satiety responses and insulin release. Glucagon-like 109 
peptide 1 (GLP-1) is an intestinal gut hormone with important physiological roles including 110 
appetite control and is key in the regulation of post-prandial increases in insulin secretion, 111 
thereby regulating levels of glycaemia (Baggio and Drucker, 2007; Drucker, 2006). GLP-1 112 
mediates its effects through the GLP-1 receptor (GLP-1R) which is a G-protein coupled 113 
receptor (GPCR) expressed in a wide range of human tissues including α, β and δ- cells of the 114 
pancreatic islets, lung, kidney, heart, intestine, stomach, skin, vagal nerve and several regions 115 
of the central nervous system (CNS) including the hypothalamus and brainstem. GLP-1Rs 116 
have been shown to rapidly internalise following activation by GLP. A study by Kuna et al., 117 
2013 demonstrated that GLP-1 receptor internalisation was induced by 0.1 μM GLP-1 2 118 
minutes to 1 h. Internalised receptors are then either recycled back to the cell surface where 119 
they can again engage with ligands, or  are targeted for post-endocytic degradation, which 120 
results in permanent signal termination from the receptor (Noerklit et al., 2014). 121 
GLP-1 is well established to regulate bodyweight by stimulating feelings of satiety via GLP-122 
1R in the brain (Baggio and Drucker, 2007; Drucker, 2006). In addition to the most well 123 
characterised effect, the amplification of glucose-stimulated insulin secretion, GLP-1 is now 124 
known to induce expansion of insulin-secreting β-cell mass. The mechanism by which GLP-1 125 
is believed to enhance insulin secretion is through the regulation of ion channels (including 126 
ATP-sensitive K+ channels, voltage-dependent Ca2+ channels, voltage-dependent K+ 127 
channels, and nonselective cation channels) and by the regulation of intracellular energy 128 
homeostasis and exocytosis (Macdonald et al., 2002). A number of clinical trials have been 129 
conducted in order to investigate the weight loss effect of GLP-1R agonist therapies in 130 
diabetic patients. A correlation between these therapies and weight loss has been established 131 
with the GLP-1R agonist liraglutide having a significant positive effect on weight loss (Buse 132 
et al., 2013). 133 
Hosaka et al., (2012) investigated the effect of a lipid-containing meal with added MSG 134 
(2000 mg/meal) on glucose homeostasis, incretin secretion and gastric emptying in humans. 135 
GLP-1 plasma levels were significantly increased (although the mechanism for this was not 136 
determined). One possible mechanism could be through the interaction of the GLP-1R. It is 137 
well-established that sustained GLP-1R antagonism (with exendin (9-39)) impairs glucose 138 
tolerance, decreases insulin secretion and causes hyperglycaemia (D’Alessio et al., 1996; 139 
Edwards et al., 1999; Kolligs, Fehmann et al., 2002; Green et al., 2005; Scrocchi et al., 140 
1996). As MSG is proposed to be an obesogen it seems logical to investigate whether it can 141 
disrupt the GLP-1/GLP-1R axis. 142 
This is the first study assessing a potential obesogenic mechanism for MSG and the aims are 143 
to primarily investigate 3 h and 72 h exposure effects of MSG on GLP-1 secretion in vitro 144 
and also to investigate any potential mechanisms through 1) examining 3 h and 72 h toxicity 145 
of MSG on enteroendocrine (EE) cells (pGIP/neo: STC-1 cells, a sub-clone of the STC-1 cell 146 
line which secretes GLP-1) including measures of subtle pre-lethal cytotoxicity and 2) 147 
studying the endocrine disrupting potential of MSG on the GLP-1 receptor using a GLP-1R 148 
redistribution assay and high content analysis (HCA). 149 
 150 
2. Materials and methods 151 
2.1. Chemicals and reagents 152 
Cell culture reagents and Hank’s Balanced Salt Solution (HBSS) were supplied by Life 153 
Technologies (Paisley, UK). The reference standard GLP-1 (7-37) was obtained from Abcam 154 
(Cambridge, UK). MSG, thiazolyl blue tetrazolium bromide (MTT) and formalin were all 155 
supplied by Sigma-Aldrich (Poole, Dorset, UK). Hoechst nuclear stain and mitochondrial 156 
membrane potential dye were provided by Thermo Scientific (UK). GLP-1 ELISA kits were 157 
purchased from Millipore (Billerica, MA, USA).  All other reagents were standard laboratory 158 
grade. 159 
 160 
2.2. Cell culture 161 
The U2OS-GLP1R-EGFP cell line (a U2OS cell line with stable expression of the human 162 
GLP-1R with a C-terminal EGFP tag) was obtained from Thermo Scientific (UK) and grown 163 
in 75 cm2 tissue culture flasks (Nunc, Roskilde, Denmark) at 37 °C with 5% CO2 and 95% 164 
humidity. The cells were cultured routinely in Dulbecco’s modified Eagle medium (DMEM) 165 
media with Glutamax, 10% foetal bovine serum (FBS), 1% penicillin and streptomycin (50 166 
U/ml) and 50 mg/ml G418. Cells were grown in plating media (DMEM with Glutamax, 1% 167 
FBS, 1% penicillin and streptomycin (50 U/ml)) for 24 h prior to running the assay. Test 168 
compounds and standards were diluted in assay media (DMEM with Glutamax, 1% penicillin 169 
and streptomycin (50 U/ml)). The assay has been validated with cells up to a passage of 30 170 
(Thermo Scientific, UK). 171 
pGIP/neo: STC-1 cells are an enteroendocrine (EE) cell model and its GLP-1 secretory 172 
ability has been extensively investigated (Gillespie et al., 2015; Jafri et al., 2016). These were 173 
a gift from Dr. B. Wice (Washington University of St. Louis) with permission from Dr. D. 174 
Hanahan (University of California, San Francisco, CA). Cells were cultured DMEM with 175 
Glutamax, 10% FBS, 1% penicillin and streptomycin (50 U/ml) and 50 mg/ml G418. Cells 176 
were passaged at 80-90% confluence and used between passages 15-50. 177 
 178 
2.3. Cell viability 179 
In addition to visual inspection of cells under the microscope to evaluate cell morphology and 180 
attachment, two cell viability assays were used to assess cytotoxic effects of MSG exposure. 181 
2.3.1. MTT 182 
The thiazolyl blue tetrazolium bromide (MTT) assay was used to monitor the cytotoxic 183 
effects of MSG test concentrations in the U2OS-GLP1R-EGFP cell line. Viable cells convert 184 
the soluble yellow MTT into insoluble purple formazan by the action of mitochondrial 185 
succinate dehydrogenase. For the U2OS-GLP1R-EGFP cells, clear flat-bottomed 96-well 186 
plates (Nunc, Roskilde, Denmark) were seeded with 6 x 104 cells and the test compound was 187 
added after 24 h and incubated for a further 1 h. The supernatant was discarded and 50 µl of 188 
MTT solution/well (5mg/ml stock in phosphate buffered saline (PBS) diluted in 1:2.5 in 189 
assay media) was added and cells were incubated for a further 3 h. Again, supernatant was 190 
removed and 200 µl of DMSO was added to each well (to dissolve the formazan crystals) and 191 
incubated for a further 10 min with agitation at 37 °C. Optical density was measured using a 192 
Sunrise spectrophotometer at 570 nm with a reference filter at 630 nm (TECAN, 193 
Switzerland). Samples were tested in triplicate and in three independent exposures. Viability 194 
was calculated as a percentage absorbance of the sample when compared with the absorbance 195 
of the solvent control.  196 
 197 
2.3.2. Alamar Blue 198 
The viability of the pGIP/neo: STC-1 cells in the acute and chronic study was determined 199 
using the AlamarBlue®. After removal of media for hormone analysis, 1 ml of 1:10 (v:v) 200 
AlamarBlue® in cell culture medium was added to each well and incubated for 24 h. A 100 201 
µl volume was then removed from each well and added into clear flat-bottomed 96-well 202 
microtiter plates (BD Biosciences, Bedford, MA, US). Using a Sunrise spectrophotometer 203 
(TECAN, Switzerland) the absorbance was measured at 570 nm and 600 nm. Viability was 204 
calculated as the percentage absorbance of the sample in comparison with the absorbance of 205 
the solvent control (0.1%, v:v dH20 (deionised water) in media). 206 
 207 
2.4. GLP-1R redistribution assay  208 
U2OS-GLP1R-EGFP cells were seeded (100 µl of 6 x 104 cells/well) in 96-well black plates 209 
with clear, flat bottoms. The cells were allowed to attach for 24 h before adding 100 µl of the 210 
test sample (MSG) and the GLP-1 (7-37) standards at a final dH2O and dimethyl sulfoxide 211 
(DMSO) concentration of 0.2%. To assess whether MSG had a disruptive (or antagonistic) 212 
effect on the interaction of GLP-1 with the GLP-1R, the potential of MSG to influence GLP-213 
1-mediated internalisation of the EGFP-tagged GLP-1R was assessed. Thus, the ability of 214 
150 nM GLP-1 to induce internalisation of the receptor was assessed in the absence and 215 
presence of MSG.  Cells were incubated for 1 h in a 37 °C, 5% CO2, humidified incubator, 216 
before decanting buffer and fixation of the cells with 100 µl/well of formalin (approximately 217 
4% formaldehyde). Cells were incubated for a further 20 min at room temperature and then 218 
washed four times with 200 µl PBS per well per wash followed by addition of 100 µl of 1 219 
µM Hoechst staining solution (1 µl: 10 ml PBS) to each well. After 30 min, the plate was 220 
imaged on a Thermo Scientific Arrayscan HCS. The filters were set for the Hoechst dye 221 
(350/461 nm) and GFP/FITC (488/509 nm). The SpotDetectorV3 BioApplication was used 222 
for carrying out the reading step of the GLP-1R redistribution assay using the 223 
ObjectSpotAvgIntensity parameter and both data and corresponding images are generated 224 
(see Fig 1 for example of images). The assay was performed in triplicate for each 225 
experimental point and repeated in three independent exposures. The response of the cell line 226 
to the various compounds was measured and compared with the dH20 solvent control. 227 
 228 
2.5. HCA cytotoxicity assay 229 
The Cellomics® HCS reagent series multiparameter cytotoxicity assay was performed 230 
according to the manufacturer’s instructions. pGIP/neo: STC-1  cells were seeded 6 x 104 in 231 
96 well plates 24 hours prior to the assay. Briefly, mitochondrial membrane potential dye was 232 
prepared by adding 117 μl of anhydrous DMSO to make a 1 mM stock. Following incubation 233 
(3 h or 72 h), 50 μl of live cell stain was added to each well for 30 min at 37 °C and protected 234 
from light. The live stain was removed and cells were then fixed with a 10% formalin 235 
solution for 20 min at room temperature, protected from light and washed with PBS. Hoechst 236 
33342 dye at a final concentration of 1.6 µM was added to each well and incubated for 10 237 
min at room temperature and protected from light; after which cells were washed with PBS 238 
four times and evaluated on a CellInsightTM NXT High Content Screening (HCS) Platform 239 
A B  
(Thermo Fisher Scientific, UK). Hoechst stain was used to measure cell number and nuclear 240 
morphology including nuclear intensity and nuclear area while mitochondrial membrane 241 
potential dye was used to measure mitochondrial health, specifically mitochondrial 242 
membrane potential and mitochondrial mass. Data were captured for each plate using a × 10 243 
objective magnification in the selected excitation and emission wavelengths of Hoechst dye 244 
(Ex/Em 350/461 nm) and mitochondrial membrane potential dye (Ex/Em 554/576 nm). For 245 
each well, 25 field of view images were acquired to examine each parameter with each image 246 
containing approximately 6,000 cells. 247 
 248 
2.6. GLP-1 secretion studies  249 
2.6.1. 3 h exposure 250 
The pGIP/neo: STC-1 cells were seeded into 24-well plates (1 x 106 per well) and cultured 251 
overnight at 37 °C in a humidiﬁed atmosphere of 5% CO2. Medium was removed and cells 252 
were washed once with HBSS buffer and equilibrated for 1 h in 500 μl HBSS buffer. Test 253 
compounds (0.5, 5, 50, 250, 500 μg/ml MSG in dH20) and dH20 solvent control diluted in 254 
HBSS buffer (1000 μl) were added and allowed to incubate for a further 3 h. Supernatant was 255 
removed and stored at -20°C prior to hormone analysis.  256 
 257 
2.6.2. 72 h exposure 258 
Initially cells were seeded into 96 well plates (5 x 104 per well) and cultured overnight at 37 259 
°C in a humidiﬁed atmosphere of 5% CO2. Test concentrations (0.5, 5, 50, 250, 500 μg/ml 260 
MSG in dH20) and dH20 solvent control diluted in reduced serum media (1% serum) (100 μl) 261 
were added and allowed to incubate for 72 h. Media from each well was harvested and 262 
retained at 24 h intervals and replaced by fresh media containing the appropriate 263 
concentration of MSG or vehicle control. Samples were stored at -20 °C until immediately 264 
before assay of the GLP-1 content at which time the 3 x 200 μl samples from each well were 265 
pooled. 266 
 267 
2.7. Hormone Analysis 268 
GLP-1 was measured using a Glucagon Like Peptide-1 (GLP-1) (Active) ELISA kit (EGLP-269 
35K; in accordance with the manufacturer’s instructions (Millipore, Watford, UK). All 270 
experiments were performed in triplicate for each experimental point and repeated in three 271 
independent experiments. Responses of cells to the test compound were compared with the 272 
negative control (dH20, 0.1%). 273 
 274 
2.8. Statistical Analysis 275 
All values shown are expressed as mean ± standard error of the mean (SEM) of the three 276 
independent exposures for MSG. Data from the cell viability, GLP-1R redistribution assay 277 
and GLP-1 ELISA were analysed using Microsoft Excel and GraphPad PRISM 5 software 278 
(GraphPad Software Inc, San Diego, CA). A one-way analysis of variance (ANOVA) 279 
followed by Dunnett’s multiple comparison test was used to determine significant differences 280 
between treatments and the corresponding control. A P-value of < 0.05 was considered as 281 
significant (P < 0.05 *, P < 0.01 ** and P < 0.001 ***). 282 
3. Results  283 
3.1. Cell viability data 284 
Viability of the pGIP/neo: STC-1 cells was not affected by any concentration of MSG during 285 
either the acute or the chronic study, as determined by AlamarBlue® assay (P > 0.05) (data 286 
not shown). Although not significantly different, there was some evidence of reduced 287 
viability at higher concentrations of MSG at 72 h. However as this is a relatively insensitive 288 
assay there was sufficient justification for looking at potential cytotoxic markers on HCA. 289 
Similiarly, MTT assays showed no significant change in viability of the U2OS-GLP1R-EGFP 290 
cells following 1 h exposure to MSG (0.5, 5, 50, 250 and 500 μg/ml) (data not shown).  291 
 292 
3.2. Effects of MSG on GLP-1 secretion 293 
3.2.1. Effects of 3 h exposure of MSG on GLP-1 secretion 294 
Following 3 h exposure of pGIP/neo: STC-1 cells to lower MSG concentrations (0.5-250 295 
μg/ml) did not significantly affect GLP-1 secretion. However, at 500 μg/ml, MSG stimulated 296 
a signiﬁcant 9.6 pg /106 increase in GLP-1 secretion (22.4 pg /106 cells in 500 μg/ml MSG vs. 297 
12.8 pg /106 cells in control; P < 0.001) (Fig.2). 298 
 299 
3.2.2. Effects of 72 h exposure of MSG on GLP-1 secretion 300 
Similarly 72 h exposure of pGIP/neo: STC-1 cells to lower MSG concentrations (0.5-250 301 
μg/ml) did not significantly affect GLP-1 secretion. However, at 500 μg/ml MSG there was a 302 
significant decrease in GLP-1 secretion by 35.9 pg/106 cells (45.4 pg /106 cells in 500 μg/ml 303 
MSG vs 81.4 pg /106 cells in control  P < 0.05) (Fig.3). 304 
 305 
3.3. Cytotoxicity 306 
The potential cytotoxicity of either 3 h or 72 h exposure to MSG (0.5, 5, 50, 250 and 500 307 
μg/ml) on pGIP/neo: STC-1 intestinal cells was assessed by HCA analysis by measuring cell 308 
number and nuclear morphology including nuclear intensity, and nuclear area.  309 
Mitochondrial membrane potential dye was used to measure mitochondrial health, 310 
specifically mitochondrial membrane potential and mitochondrial mass. For 3 h MSG 311 
exposure no cytotoxicity was observed at any MSG concentrations (data not shown).  312 
However, following 72 h exposure, 250 μg/ml MSG decreased cell number by 11.8% (P < 313 
0.05), increased nuclear area by 23.9% (P < 0.001) and decreased mitochondrial membrane 314 
potential by 13% (P < 0.05). MSG (500 μg/ml) decreased cell number by 26.7% (P < 0.001), 315 
increased nuclear area by 29.8% (P < 0.001), increased mitochondrial mass by 16.3% (P < 316 
0.01) and decreased mitochondrial membrane potential by 21.6% (P < 0.001) (Fig. 4 and 5). 317 
 318 
3.4. GLP-1R internalisation assay 319 
A standard curve was generated using various concentrations of GLP-1 (1-300 nM) to drive 320 
receptor internalisation (Fig.6). The EC50 value was calculated as 37 nM GLP-1. 321 
MSG did not cause internalization of the GLP-1R in U2OS-GLP1R-EGFP cells. 322 
Furthermore, exposure to MSG (0.5-500 μg/ml) during the period of exposure to GLP-1 did 323 
not affect GLP-1-mediated internalisation of the GLP-1R (Figure 7).   324 
A B B 
 325 
4. Discussion 326 
Associations between MSG consumption and increased incidence of diabetes and obesity 327 
have been reported in both human and animal studies (He et al., 2011; Insawang et al. 2012; 328 
Miskowiak et al., 1993). However, a potential mechanism has not yet been identified. This 329 
study hypothesised that MSG might interact with the GLP-1 hormone, either through the 330 
GLP-1R or by affecting GLP-1 secretion. For an obesogen, GLP-1 is a plausible potential 331 
target given its pleiotropic actions on satiety responses, post-prandial insulin and glucagon 332 
secretion, gut motility, and gastric acid secretion.The present study investigated whether 333 
MSG has a disrupting effect on the secretion of the incretin hormone GLP-1 or its interaction 334 
with its receptor. Cytotoxic responses were evaluated in pGIP/neo: STC-1 cells, an EE cell 335 
model which secretes GLP-1. EE cells are one of four subtypes of epithelial cells lining the 336 
gut (Beucher et al., 2012) and collectively are the largest endocrine system in the body. The 337 
cells used in this study (pGIP/neo: STC-1) are a sub-clone of the STC-1 cell line which 338 
secretes GLP-1 (Gillespie et al., 2015; Jafri et al., 2016). Recent studies suggest that EE cells 339 
are more flexible than previously thought because they alter the profile of hormones made 340 
and released in response to nutrient changes in the diet (Habib et al. 2012). As pGIP/neo: 341 
STC-1 cells are a pluri-hormonal EE cell line (also secreting cholecystokinin, peptide YY and 342 
glucose-dependent insulinotropic polypeptide) (Hand et al., 2012) that imitate some of the 343 
other hormonal influences which exist in the intestine in vivo such as having the potential to 344 
release other gut hormones. 345 
A previous study on the STC-1 parental cells provides evidence that exposure to MSG can 346 
activate the nutrient sensing T1R1/T1R3 (taste receptors) umami receptor. Additionally, 347 
MSG exposure to the STC-1 cells induced neurotensin (NT) release, a peptide involved in the 348 
regulation of hormone release from the gut (Kendig et al., 2015). However, in the present 349 
study the potential of MSG to interfere with GLP-1 interaction with the GLP-1R was 350 
examined and under all of the various test conditions there was no evidence of this. It is 351 
important to mention that the cell lines used for the present study and the Kendig et al., 352 
(2015) study differ,as well as the receptor investigated, therefore accounting for differences 353 
in findings. 354 
When studying the effects of MSG on intestinal EE cells, which produce and release GLP-1, 355 
3 h exposure of MSG stimulated GLP-1 secretion with a concentration 500 μg/ml almost 356 
doubling the amount of hormone that is released. Previously, it has been demonstrated in vivo 357 
that an acute bolus of MSG increases plasma GLP-1 in healthy male volunteers (Hosaka et al. 358 
2012). The present data suggest that this could be a consequence of a direct effect of MSG on 359 
GLP-1 secretion by EE cells.  360 
Secretion of GLP-1 occurs primarily in response to nutrient ingestion, particularly glucose 361 
and fat and to a lesser extent specific amino acids and protein hydrosylates (Elliott et al., 362 
1993, Ramshur et al., 2002). However, it may not solely be the presence of nutrients that 363 
stimulates secretion. A biphasic release of GLP-1 into the circulation following a meal has 364 
been established (Rask et al., 2001) which would suggest the potential input of neural and 365 
endocrine factors. It is believed that GLP-1 secretion may prove even more complex than 366 
other gut hormones. In particular, glutamine, a breakdown product of MSG, may be even 367 
more effective than glucose or other amino acids as a GLP-1 secretagogue. Glutamine 368 
triggers membrane depolarisation and increases intracellular calcium; however asparginine 369 
and alanine also increase intracellular calcium without increasing GLP-1 secretion (Reimann 370 
et al., 2004). In the presence of diazoxide (a potassium channel activator) and a depolarising 371 
concentration of potassium chloride, glutamine still enhanced GLP-1 secretion (Reimann et 372 
al., 2004), therefore glutamine-induced GLP-1 secretion may not be exclusively dependent 373 
on membrane polarisation. Therefore, the mechanism by which MSG induced an increase in 374 
GLP-1 secretion following 3 h exposure, may have been consequential of the breakdown 375 
product of MSG, glutamine. The paracrine actions of somatostatin, secreted from 376 
neighbouring D-cells exerts an inhibiting effect on GLP-1 secretion and may prove pivotal in 377 
producing a feedback loop for GLP-1 regulation following nutrient ingestion (Hansen et al., 378 
2000; Lahlou et al., 2004). Previous studies using the parental STC-1 cell line have 379 
demonstrated that exposure to glutamine elevated the intracellular Ca2+ levels (Miyata et al., 380 
2014). It may be via this mechanism that the GLP-1 secretion is increased following 3 hour 381 
exposure to higher concentrations of MSG  382 
MSG is consumed on a daily basis and is present in a wide variety of foods and therefore it 383 
was logical to examine the effects of a longer exposure on GLP-1 secretion (72 h) mimicking 384 
daily consumption. When pGIP/neo STC-1 cells were exposed to MSG for 72 h ,a 385 
detrimental effect on GLP-1 secretion leading to a 1.8-fold reduction in the amount of 386 
hormone released was observed. A possible explanation for the chronic decrease in GLP-1 387 
secretion is that MSG-induced stimulation of GLP-1 secretion (as observed with 3 h 388 
exposure) leads to a depletion in the capacity of EE cells to secrete GLP-1. However this 389 
would need to be studied in more detail with further investigations. This observation has 390 
potential physiological relevance given that GLP-1 secretion may be blunted/impaired in 391 
patients with type 2 diabetes. For example, reduced postprandial concentrations of intact 392 
biologically active GLP-1 have been observed in type 2 diabetic patients and it seem likely 393 
that that these reductions in GLP-1 secretion result in impaired insulin secretion (Vilsbøll et 394 
al., 2001). Therefore our observation that 72 h MSG exposure leads to a decline in GLP-1 395 
secretion suggests that it may be a contributing factor in the pathogenesis of diabetes/obesity.  396 
A novel HCA assay measuring nuclear and mitochondrial parameters was developed to 397 
assess the cellular health of EE cells under conditions of both 3 h and 72 h MSG exposure. 398 
No cytotoxicity was evident when the EE cells were exposed to MSG for 3 h, however, 399 
significant toxic effects were observed following 72 h exposure.  Concentration-dependent 400 
reductions in cell number and in mitochondrial membrane potential were observed, as were 401 
increases in nuclear area and mitochondrial mass.  402 
MSG exposure studies are scarce in the literature. However, several in vivo single-dose 403 
studies have shown the potential of MSG to impact negatively upon cells and ultimately lead 404 
to cell death. One study investigated the exposure of rat thymocytes to MSG (4 mg/g body 405 
weight) and found a dose-dependent decrease in cell survival with cell loss occurring 406 
primarily through apoptosis (Pavlovic et. al., 2009). Increased apoptosis can arise from the 407 
absence of survival factors and cell-to-cell signalling mechanisms that are present in vivo 408 
(Elmore, 2007). The concentration-dependent manner in which MSG induces apoptosis has 409 
been noted previously whereby glutamate-induces cell death via apoptosis or necrosis 410 
(Ankarcrona et. al., 1995).  The results of the present study provide no evidence of 3 h toxic 411 
effects, but again this can be due to a number of other factors including the cell type used, the 412 
MSG concentrations employed and the duration of exposure. 413 
In the present study there was a good association between the MSG concentrations that 414 
caused decline in GLP-1 secretion and those which caused cytotoxic effects.  At the highest 415 
MSG concentration tested (500 μg/ml) there was a significant decrease in both cell number 416 
and in mitochondrial membrane potential but a significant increase in mitochondrial mass and 417 
nuclear area. It is well established that biogenesis of mitochondria can increase mitochondrial 418 
mass as a result of increased mitochondrial respiration, and that this usually corresponds with 419 
reduced mitochondrial membrane potential (O'Brien and Haskins, 2007). Mitochondria are 420 
organelles involved in the regulation of programmed cell death (apoptosis). This often occurs 421 
when cells are damaged by disease or toxic agents (Norbury and Hickson, 2001). Due to the 422 
increase in nuclear area observed in the study, it would appear that some cells underwent 423 
necrosis. In the case of necrosis, the cells will swell and consequently cause an increase in 424 
nuclear area, as observed in the present study. Although there are distinct differences in the 425 
mechanisms of apoptosis and necrosis, there is overlap between the two processes described 426 
as the “apoptosis-necrosis continuum” (Zeiss, 2003) and the results of the HCA assays 427 
suggest that the highest concentration (500 μg/ml) of MSG is capable of inducing “apoptosis-428 
necrosis continuum”  in EE cells during the 72 h exposure. 429 
The concentrations of MSG used in this study were based on dietary exposure levels, average 430 
daily intakes across different populations and at levels higher than these levels to account for 431 
underestimations in MSG intake (Collision et al., 2009; He et al., 2011; Nakanishi et al., 432 
2008; Shi et al., 2014). Maximum MSG solubility was achieved at 500 mg/ml, giving a top 433 
concentration on the assay plate of 500 μg/ml, equivalent to an exposure of 30 g/day. 434 
Although this is much higher than average daily intakes discussed, as outlined in the 435 
introduction, restaurants add unknown amounts of MSG to foods, therefore it is difficult to 436 
estimate accurate exposure and it is therefore possible certain groups of the population could 437 
be exposed to these high levels, where the present study found significant effects. 438 
Furthermore, in a society where MSG is not regulated and consumers are increasingly eating 439 
out or purchasing take-away foods, it is not unreasonable to suggest that MSG exposure is 440 
likely to be on the increase. It is also worth mentioning the potentially greater health risks 441 
which Asian populations are being subjected to as a result of their excessive MSG exposure. 442 
Large scale epidemiological studies are clearly warranted to provide better estimates of MSG 443 
consumption. The setting of maximum levels of MSG content in foods is something which 444 
should be given serious consideration. This would have the added benefit of improving the 445 
accuracy of consumer exposure for this food additive.  446 
 447 
Conclusion 448 
This is the first study to examine a potential endocrine disrupting effect of MSG, a suspected 449 
obesogen, on the interaction with the GLP-1 hormone.  This study demonstrates that MSG, 450 
has the ability to stimulate GLP-1 secretion from pGIP/neo: STC-1 cells, an EE cell model 451 
following 3 h exposure, but that longer-term exposure leads to impaired GLP-1 secretion and 452 
a range of changes indicative of cytotoxicity. The multi-parameter HCA cytotoxicity assay 453 
utilised here was able to detect subtle changes in cell health and this has great potential for 454 
investigating the potential endocrine disrupting effects of other putative obesogens.  455 
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Figure legends 619 
Fig. 1: Images illustrating the GLP-1R redistribution. A) DMSO control and B) treated with 620 
agonist GLP-1 (300 nM). Typical HCA micrographs are shown with nuclei (blue) and GLP-621 
1R ﬂuorescence (green) X 20 objective magnification. 1B shows GLP-1R-EGFP 622 
internalisation that is detected by the image analysis algorithm. 623 
Fig. 2. GLP-1 secretory responses of pGIP/neo: STC-1 cells during acute (3 h) exposure to 624 
MSG. Graph shows GLP-1 secretion from pGIP/neo: STC-1 cells (mean ± SEM, n = 3) 625 
following 3 h incubation with 0.5-500 μg/ml MSG. 626 
Fig. 3. GLP-1 secretory responses of pGIP/neo: STC-1 cells during chronic (72 h) exposure 627 
to MSG. Graph shows GLP-1 secretion from pGIP/neo: STC-1 cells (mean ± SEM, n = 3) 628 
following 72 h incubation with 0.5-500 μg/ml MSG. P < 0.05 (*) represent significance. 629 
Fig. 4: Cytotoxic effects on pGIP/neo STC-1 cells of MSG 0.5- 500 μg/ml following 72 h 630 
exposure. A number of endpoints were measured including a) Cell number, b) Nuclear area, 631 
c) Nuclear Intensity, d) Mitochondrial mass and e) Mitochondrial membrane potential. Data 632 
are expressed as a percentage of solvent control (dH20) for each parameter. Data are mean ± 633 
SEM, n=3; P < 0.05 (*) < 0.01 (**) < 0.001 (***) versus appropriate control. 634 
Fig. 5: HCA images for a) solvent control and b) MSG-treated (500 μg/ml) following 72 h 635 
exposure of pGIP/neo: STC-1 cells. Each image was acquired at × 10 objective 636 
magnification using Hoechst dye (blue; nuclear staining) and mitochondrial potential dye 637 
(red; mitochondrial staining). 638 
Fig. 6: GLP-1 standard curve (1-300 nM) relative to the DMSO negative control in the 639 
U2OS-GLP1R-ERFP cell line. Data are mean+sem, n=3. GLP-1R internalisation was 640 
normalised to vehicle control (0.2% DMSO) and 300 nM GLP-1 (100%). The  EC50 value 641 
was calculated at 37 nM. 642 
Figure 7: Images illustrating the GLP-1R redistribution assay following MSG exposure. A) 643 
DMSO control, B) treated with MSG 500 μg/ml C) Positive control (GLP-1 150 nM) and D) 644 
MSG 500 μg/ml and GLP-1 150 nM. Typical HCA micrographs are shown with nuclei (blue) 645 
and GLP-1R ﬂuorescence (green) X 20 objective magnification.  646 
